Additive antisense effects of different PNAs on the in vitro translation of the PML/RARalpha gene.

Por Mologni, L, leCoutre, P, Nielsen, P E, Gambacorti-Passerini, C
Publicado em 1998

Phase I Study of INNO-406, a Dual Abl/Lyn Kinase Inhibitor, in Philadelphia Chromosome-Positive Leukemias Post-Imatinib Resistance or Intolerance

Por Kantarjian, H., le Coutre, P., Cortes, J., Pinilla-Ibarz, J., Nagler, A., Hochhaus, A., Kimura, S., Ottmann, O.
Publicado em 2010

OS08.8 A head-to-head comparison of two different high dose methotrexate (HDMTX) - and high dose cytarabin (HDAraC)-based chemotherapy regimens in younger patients with primary cen...

Por Rieger, L., Schlegel, U., Le Coutre, P., Seidel, S., Leonards, J., Martus, P., Mathas, S., Janz, M., Korfel, A.
Publicado no Neuro Oncol (2017)

Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials

Por le Coutre, P D, Hughes, T P, Mahon, F-X, Kim, D-W, Steegmann, J L, Shah, N P, Gooden, K, Wallis, N, Cortes, J E
Publicado no Leukemia (2016)

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

Por Hochhaus, A, Saglio, G, Hughes, T P, Larson, R A, Kim, D-W, Issaragrisil, S, le Coutre, P D, Etienne, G, Dorlhiac-Llacer, P E, Clark, R E, Flinn, I W, Nakamae, H, Donohue, B, Deng, W, Dalal, D, Menssen, H D, Kantarjian, H M
Publicado no Leukemia (2016)

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

Por Steegmann, J L, Baccarani, M, Breccia, M, Casado, L F, García-Gutiérrez, V, Hochhaus, A, Kim, D-W, Kim, T D, Khoury, H J, Le Coutre, P, Mayer, J, Milojkovic, D, Porkka, K, Rea, D, Rosti, G, Saussele, S, Hehlmann, R, Clark, R E
Publicado no Leukemia (2016)

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study

Por Hochhaus, A, Masszi, T, Giles, F J, Radich, J P, Ross, D M, Gómez Casares, M T, Hellmann, A, Stentoft, J, Conneally, E, García-Gutiérrez, V, Gattermann, N, Wiktor-Jedrzejczak, W, le Coutre, P D, Martino, B, Saussele, S, Menssen, H D, Deng, W, Krunic, N, Bedoucha, V, Saglio, G
Publicado no Leukemia (2017)

Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study

Por Hochhaus, A, Rosti, G, Cross, N C P, Steegmann, J L, le Coutre, P, Ossenkoppele, G, Petrov, L, Masszi, T, Hellmann, A, Griskevicius, L, Wiktor-Jedrzejczak, W, Rea, D, Coriu, D, Brümmendorf, T H, Porkka, K, Saglio, G, Gastl, G, Müller, M C, Schuld, P, Di Matteo, P, Pellegrino, A, Dezzani, L, Mahon, F-X, Baccarani, M, Giles, F J
Publicado no Leukemia (2016)

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

Por Cortes, J.E., Kim, D.-W., Pinilla-Ibarz, J., le Coutre, P., Paquette, R., Chuah, C., Nicolini, F.E., Apperley, J.F., Khoury, H.J., Talpaz, M., DiPersio, J., DeAngelo, D.J., Abruzzese, E., Rea, D., Baccarani, M., Müller, M.C., Gambacorti-Passerini, C., Wong, S., Lustgarten, S., Rivera, V.M., Clackson, T., Turner, C.D., Haluska, F.G., Guilhot, F., Deininger, M.W., Hochhaus, A., Hughes, T., Goldman, J.M., Shah, N.P., Kantarjian, H.
Publicado em 2013

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure

Por Hughes, T.P., Mauro, M.J., Cortes, J.E., Minami, H., Rea, D., DeAngelo, D.J., Breccia, M., Goh, Y.-T., Talpaz, M., Hochhaus, A., le Coutre, P., Ottmann, O., Heinrich, M.C., Steegmann, J.L., Deininger, M.W.N., Janssen, J.J.W.M., Mahon, F.-X., Minami, Y., Yeung, D., Ross, D.M., Tallman, M.S., Park, J.H., Druker, B.J., Hynds, D., Duan, Y., Meille, C., Hourcade-Potelleret, F., Vanasse, K.G., Lang, F., Kim, D.-W.
Publicado no N Engl J Med (2019)